Log in or Sign up for Free to view tailored content for your specialty!
Infection News
Convalescent plasma reduces hospitalization risk in COVID-19
Convalescent plasma, when administered within 9 days of symptom onset in patients with COVID-19, may reduce the risk for hospitalization, according to data published in The New England Journal of Medicine.
EULAR takes ‘precautionary position’ in support of third, booster COVID-19 vaccine doses
Citing a lack of available data and time, EULAR has taken a “precautionary position” in support of third and booster COVID-19 vaccine doses for patients with rheumatic and musculoskeletal diseases.
Log in or Sign up for Free to view tailored content for your specialty!
Questions remain about mechanisms behind multisystem inflammatory syndrome in children
PHOENIX — Although the CDC has presented a case definition of multisystem inflammatory syndrome in children, the COVID-19 complication continues to demand attention from researchers and providers alike.
Sotrovimab no longer authorized to treat COVID-19 in areas with high BA.2 frequency
The monoclonal antibody sotrovimab is no longer authorized by the FDA to treat COVID-19 in certain U.S. regions with high frequency of the omicron BA.2 subvariant.
Worse COVID-19 outcomes in lupus driven by demographics, untreated disease
Worse COVID-19 outcomes in patients with systemic lupus erythematosus are driven by comorbidities, demographics and untreated or active disease, according to data published in the Annals of the Rheumatic Diseases.
mRNA COVID-19 vaccines offer ‘quite encouraging’ long-term protection
mRNA vaccines yielded not only strong short-term immune response against COVID-19, but also persistent immunity through at least 6 months, said a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.
COVID-19 unlikely to ‘fade away’ for the immunocompromised: ‘It’s good to have options’
COVID-19 fears and complications are likely to persist far into the future for immunocompromised individuals, a speaker noted at the Basic and Clinical Immunology for the Busy Clinician symposium.
‘Can we do any better?’: Biomarkers, more data needed to reduce cytokine storm mortality
A more nuanced understanding of COVID-19-related cytokine storm syndrome may hold the key to minimizing fatalities, noted a presenter at the Basic and Clinical Immunology for the Busy Clinician symposium.
Intersection of ‘highly heterogenous’ COVID-19, IMIDs remains ‘poorly understood’
Scientific advancement has yielded slow but steady progress in the understanding of COVID-19, particularly in patients with immune-mediated conditions, a presenter said at the Basic and Clinical Immunology for the Busy Clinician symposium.
Shifting ‘definition of fully vaccinated’ muddles COVID-19 vaccine efficacy data for IMIDs
An evolving definition of “fully vaccinated” has made it difficult to assess the utility and success of COVID-19 vaccines among patients with immune-mediated inflammatory diseases, a presenter noted here.
-
Headline News
CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots
November 18, 20241 min read -
Headline News
Obesity drugs could help lower alcohol intake
November 18, 20243 min read -
Headline News
Pediatric asthma ‘potential source of cognitive difficulty’
November 18, 20242 min read
-
Headline News
CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots
November 18, 20241 min read -
Headline News
Obesity drugs could help lower alcohol intake
November 18, 20243 min read -
Headline News
Pediatric asthma ‘potential source of cognitive difficulty’
November 18, 20242 min read